Juan Maldonado, MD
Family Medicine · Harlingen, TXNPI 1114901626
Payments from drug & device makers
Across 327 payments — averaging $14.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$899
- AstraZeneca$368
- Boehringer Ingelheim$307
- Sanofi-aventis U.S. LLC$226
- Pfizer$190
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,64199%
- Education$481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 95 | $1,065 |
| Novo Nordisk | 79 | $899 |
| AstraZeneca | 19 | $368 |
| Boehringer Ingelheim | 16 | $307 |
| Sanofi-aventis U.S. LLC | 14 | $226 |
| Pfizer | 11 | $190 |
| Johnson & Johnson | 11 | $182 |
| Amarin Pharma, Inc. | 12 | $169 |
| Access Pro Medical, LLC | 1 | $131 |
| Amgen | 7 | $118 |
| Dexcom, Inc. | 6 | $103 |
| Teva Pharmaceuticals USA, Inc. | 5 | $82 |
| Abbott | 5 | $82 |
| Exact Sciences | 4 | $81 |
| Novartis | 5 | $79 |
| Bayer | 4 | $72 |
| Mylan Specialty L.p. | 4 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $54 |
| AbbVie | 4 | $54 |
| GSK | 3 | $48 |
| Smith+Nephew | 2 | $35 |
| Si-bone, Inc. | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Paratek Pharmaceuticals, Inc. | 2 | $30 |
| Mannkind Corporation | 1 | $21 |
| Radius Health, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Matriderm$131
How this compares
$4,689 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 83 | $81,565 |
| FarxigaDapagliflozin Propanediol | 69 | $80,455 |
| JardianceEmpagliflozin | 86 | $78,129 |
| OzempicSemaglutide | 48 | $72,562 |
| MounjaroTirzepatide | 29 | $36,403 |
| JanuviaSitagliptin Phosphate | 28 | $31,565 |
| XareltoRivaroxaban | 18 | $31,372 |
| TrulicityDulaglutide | 14 | $23,603 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $14,958 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $14,658 |
| EntrestoSacubitril/Valsartan | 12 | $9,227 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $7,223 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $6,387 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $6,054 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $4,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $307 | $84,18397 claims |
| PfizerEliquis, Paxlovid | $190 | $82,994106 claims |
| AstraZenecaFarxiga | $368 | $80,45569 claims |
| Novo NordiskOzempic | $899 | $72,56248 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,065 | $60,00643 claims |
| MerckJanuvia, Janumet | $17 | $46,22343 claims |
| Johnson & JohnsonXarelto | $182 | $31,37218 claims |
| NovartisEntresto | $79 | $9,22712 claims |
| GSKBreo Ellipta | $48 | $7,22315 claims |
| AbbVieSynthroid | $54 | $87115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Harlingen
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.